XBiotech Inc.

What they do

XBiotech is a pharmaceutical preparations company incorporated in British Columbia and headquartered in Austin, Texas. It conducts research and development of therapeutic antibodies and vaccines, and per its filings its activities center on preclinical studies and clinical trials of product candidates. It currently generates no product revenue; revenue reported in prior years came from sources other than commercial sales, and annual revenue was $0.00 in 2019 and 2023 and $0.00 in each quarter of 2023. The company employs a small leadership team, including Dr. Sushma Shivaswamy as Interim Chief Executive Officer and Chief Scientific Officer and Angela Hu as Director of Finance.

Revenue drivers

• Product sales — No approved product is described in the excerpts; annual revenue was $0.00 in 2019 and 2023 and $0.00 in every quarter of 2023.
• Prior-year revenue items — Annual revenue was $44.0M in 2020, $18.4M in 2021, $4.0M in 2022 and $0.00 in 2023, but the excerpts do not identify what generated these amounts.
• Balance-sheet funding — Operations are funded from existing cash rather than revenue; cash and equivalents were $109.5M at 2026-06-30 against total assets of $133.7M.

Recent performance

Annual revenue fell from $44.0M in 2020 to $4.0M in 2022 and $0.00 in 2023, and quarterly revenue was $0.00 in each quarter of 2023. Net losses widened from $17.4M in 2021 to $24.6M in 2023, $38.5M in 2024 and $45.5M in 2025, with diluted EPS of -$0.58, -$0.81, -$1.26 and -$1.49 respectively. Operating cash flow turned negative after 2021 ($69.4M) and was -$14.8M in 2022, -$18.7M in 2023, -$31.0M in 2024 and -$39.9M in 2025. At 2026-06-30 the company reported total assets of $133.7M, total liabilities of $5.2M, shareholder equity of $128.5M and cash and equivalents of $109.5M. Diluted EPS was -$0.58 in 2021, -$1.08 in 2022, -$0.81 in 2023, -$1.26 in 2024 and -$1.49 in 2025.

Strategy

The 10-K/A is an amendment filed solely to add Part III information (Items 10–14) previously omitted, and it states it does not update other disclosures or reflect events after the original filing. Management's stated activities center on research and development programs, preclinical studies and clinical trials for product candidates, and on obtaining regulatory approval and commercializing those candidates in the United States, Europe and elsewhere. John Simard, founder, retired as President and CEO effective December 8, 2025 and continues as Chairman and Scientific Advisor; Dr. Sushma Shivaswamy serves as Interim CEO and Chief Scientific Officer. The board added Dr. Thomas Kündig, Director of the Department of Dermatology at University Hospital Zurich, in June 2025. No new product, partnership or commercial launch is described in the excerpts.

Risks

• No product revenue — Annual revenue was $0.00 in 2023 and $0.00 in each 2023 quarter, so operations depend on existing cash rather than sales.
• Widening losses — Net loss grew each year from $17.4M in 2021 to $45.5M in 2025, and operating cash flow was -$39.9M in 2025.
• Listing-rule issue — The 8-K log includes a delisting notice or listing-rule failure event dated 2025-04-07.
• Leadership transition — The founder retired as CEO effective December 8, 2025 and the current CEO is interim, with multiple director or officer change 8-Ks since late 2024.

Outlook

The excerpts do not include forward guidance, and the 10-K/A states it does not update disclosures for events after the original 10-K. The 10-Q's forward-looking statement list cites the initiation, timing, cost, progress and success of research and development programs, preclinical studies and clinical trials, and the ability to obtain regulatory approval and commercialize candidates in the United States, Europe and elsewhere. Management also cites the ability to recruit sufficient patients for future clinical trials as a forward-looking matter. No specific timeline, trial, or financial projection is provided in the source material.